ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has unveiled promising early results from its Phase 1b trial of ORIC-944, a novel PRC2 inhibitor, in combination with androgen receptor inhibitors for metastatic castration-resistant prostate cancer (mCRPC). The study reported broad and deep prostate-specific antigen (PSA) responses, with a 59% PSA50 response rate (47% confirmed, plus one pending) and a 24% confirmed PSA90 response rate.

These robust responses were seen across all dose levels and with both apalutamide and darolutamide combinations. Most patients remain on therapy, with several approaching one year or more of treatment.

ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials

A scientist examining cells in a lab, representing the company’s dedication to developing specialty pharmaceuticals.

Safety data were also encouraging: the vast majority of adverse events were mild or moderate (Grade 1 or 2), primarily gastrointestinal, supporting long-term dosing suitability. Only one patient experienced a Grade 3 event, and there were no severe (Grade 4 or 5) treatment-related adverse events. ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) plans to advance two recommended Phase 2 doses for each combination into further study, with a global Phase 3 trial set to begin in the first half of 2026.

To support these efforts, ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) announced a $125 million private placement financing led by top healthcare investors, extending its cash runway into the second half of 2027 and through the anticipated Phase 3 trial readout.

While we acknowledge the potential of ORIC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than ORIC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.